|
Sigmoid Pharma
of innovative and proprietary orally administered pharmaceutical products in the areas of transplantation, gastro-intestinal disease and neuro-degeneration.
In addition, Sigmoid selectively partners with pharmaceutical companies to enhance the therapeutic profiles of new molecules as well as existing products requiring life cycle management. Sigmoid applies its proprietary LEDDS® and SmPill® technologies to Although applicable to drugs generally, LEDDS® and SmPill® are particularly suitable for developing oral formulations for groups with special pharmaceutical needs such as children and the elderly. Sigmoid also collaborates internationally with leading academic centres of expertise in oral delivery of pharmaceuticals. |